MétaCan
Menu
Back to cohort

Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy

2013· article· en· W2332332196 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.

Bibliographic record

VenueObstetrical & Gynecological Survey · 2013
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsPrincess Margaret Cancer CentreCentre Hospitalier Universitaire de SherbrookeLondon Health Sciences CentreQueen's University
Fundersnot available
KeywordsMedicineProstate cancerAndrogen deprivation therapyAndrogenAndrogen suppressionAdverse effectRadiation therapyTestosterone (patch)Internal medicineCastrationOncologyClinical endpointQuality of life (healthcare)UrologyRandomized controlled trialCancerHormone

Abstract

fetched live from OpenAlex

Androgen deprivation with medical castration has been the mainstay treatment for metastatic prostate cancer. However, there are several drawbacks to prolonged androgen deprivation, including development of tolerance (loss of androgen dependence) and adverse effects on the quality of life. In mice tumor models of androgen dependence, castration followed by re-exposure to androgens before tumor progression preserved androgen dependence. The possible value of this treatment strategy has been studied in human prostate cancer. Several phases 2 and 3 clinical studies suggest that intermittent androgen deprivation can delay hormone resistance and provide a quality-of-life benefit. This noninferiority randomized trial compared overall survival of prostate cancer patients with use of intermittent and continuous androgen deprivation. Enrolled patients had prostatic adenocarcinoma but no metastatic disease and a rising prostate-specific antigen (PSA) level greater than 3 ng/mL after primary or salvage radiotherapy for localized prostate cancer more than 12 months before enrollment. Intermittent androgen-deprivation therapy consisted of 8-month treatment cycles, with nontreatment periods based on the PSA level. The primary study end point was overall survival. Secondary end points included time to castration-resistant disease, quality of life, and duration of nontreatment intervals. Participants were randomly assigned to intermittent therapy (n = 690) or continuous therapy (n = 696). The median follow-up was 6.9 years. No significant between-group differences in adverse events were found. With intermittent therapy, there was full testosterone recovery in 35% of patients and recovery to the trial-entry threshold in 79%. Intermittent therapy was associated with improvements in physical function and other quality-of-life measurements for hot flashes, urinary problems, fatigue, libido, and erectile function. A total of 524 patients died: 268 in the intermittent-therapy group and 256 in the continuous-therapy group. There was no difference between groups in median overall survival: 8.8 years in the intermittent-therapy group and 9.1 years in the continuous-therapy group; the hazard ratio for death was 1.02, with a 95% confidence interval of 0.86 to 1.21. With respect to the disease-specific survival, the estimated 7-year cumulative disease-related death rates were 18% in the intermittent group and 15% in the continuous group (P = 0.24). These findings show that, for overall survival, intermittent androgen deprivation is not noninferior to continuous therapy. Improvements in some quality-of-life factors are observed with intermittent therapy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.236
Threshold uncertainty score0.998

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.098
GPT teacher head0.352
Teacher spread0.254 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it